Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy.
暂无分享,去创建一个
M. Millenson | R. Ozols | L. Weiner | J. Gallo | N. Rosenblum | R. Schilder | M. Bookman | A. Rogatko | M. Boente | B. Rogers | K. Padavic-Shallers | A. Adams | S. Ciccotto | A. L. Adams
[1] M. Morgan,et al. Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial. , 1999, Gynecologic oncology.
[2] M. Millenson,et al. Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] D. Richel,et al. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] C. Pacilio,et al. Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] A. Lissoni,et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] E. Eisenhauer,et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] S Zacks,et al. Cancer phase I clinical trials: efficient dose escalation with overdose control. , 1998, Statistics in medicine.
[8] E. Venkatraman,et al. Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] A. W. Boersma,et al. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro , 1998, Cancer Chemotherapy and Pharmacology.
[10] W. Mcguire. CLINICAL STATUS AND OPTIMAL USE OF TOPOTECAN , 1997 .
[11] R. Ozols,et al. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] A Gordon,et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Pileri,et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. , 1997, The New England journal of medicine.
[14] R. Ozols,et al. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] L. Grochow,et al. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] K. Hess,et al. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] J. Beijnen,et al. Clinical Pharmacokinetics of Topotecan , 1996, Clinical pharmacokinetics.
[18] R. Ozols,et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] P B Laub,et al. NCOMP--a windows-based computer program for noncompartmental analysis of pharmacokinetic data. , 1996, Journal of pharmaceutical sciences.
[20] L. Grochow,et al. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] C. Obasaju,et al. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] N. Saijo,et al. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. , 1996, Cancer research.
[23] E. Partridge,et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, New England Journal of Medicine.
[24] T. Shea,et al. A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer. , 1995, Seminars in oncology.
[25] R. Ozols,et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] S. Rodenhuis,et al. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] H. Rosing,et al. High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. , 1995, Journal of chromatography. B, Biomedical applications.
[28] B. Barlogie,et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. , 1995, Blood.
[29] G. Rosner,et al. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] R. Motzer,et al. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. , 1994, Journal of the National Cancer Institute.
[31] G. Peters,et al. Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures. , 1994, Biochemical pharmacology.
[32] L. Saltz,et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. , 1993, Journal of the National Cancer Institute.
[33] S. Arbuck,et al. Taxol: the first of the taxanes, an important new class of antitumor agents. , 1992, Seminars in oncology.
[34] E Wiltshaw,et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] D. Ettinger,et al. Phase I and pharmacodynamic study of taxol in refractory acute leukemias. , 1989, Cancer research.
[36] R. Lipton,et al. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] E. Gluckman,et al. PROPHYLAXIS OF HERPES INFECTIONS AFTER BONE-MARROW TRANSPLANTATION BY ORAL ACYCLOVIR , 1983, The Lancet.
[38] Roger W. Jelliffe,et al. Creatinine Clearance: Bedside Estimate , 1973 .